Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Manhattan Associates Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.5 (market cap $39.89B), while Manhattan Associates Inc trades at $156.73 (market cap $9.17B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× Manhattan Associates Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MANH | |
|---|---|---|
Market Cap | $39.89B | $9.17B |
Sector | Health | Technology |
52-Week High | $491.22 | $227.94 |
52-Week Low | $278.09 | $120.88 |
Enterprise Value | $38.15B | $9.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MANH trades at $154.9, down 1.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. Recent news is dominated by an ongoing legal investigation into fiduciary duties by directors and officers.
The outlook is supported by a strong analyst consensus 'Buy' rating and a $192.80 price target, implying significant upside. Key risks include the legal investigation's outcome and potential pressure on valuation multiples, which are elevated. Revenue stability and high ROE of 96.24% underpin the fundamental case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
